Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176325 | 0.88 | CES2 (1.00) | CES2MEN1KMT2ANPSR1SRD5A2 | |
| SCHEMBL39834 | 0.85 | CES2 (0.71) | CES2MEN1KMT2ANPSR1SRD5A2 | |
| SCHEMBL30093723 | 0.85 | CES2 (0.71) | CES2MEN1KMT2ANPSR1SRD5A2 | |
| SCHEMBL11372246 | 0.84 | CES2 (0.71) | CES2MEN1KMT2ANPSR1SRD5A2 | |
| SCHEMBL11372244 | 0.84 | CES2 (0.71) | CES2MEN1KMT2ANPSR1SRD5A2 | |
| SCHEMBL4848676 | 0.83 | CES2 (0.89) | CES2MEN1KMT2ANPSR1SRD5A2 | |
| SCHEMBL4171698 | 0.83 | CES2 (0.81) | CES2MEN1KMT2ANPSR1SRD5A2 | |
| SCHEMBL29923199 | 0.83 | CES2 (0.81) | CES2MEN1KMT2ANPSR1SRD5A2 | |
| SCHEMBL19710741 | 0.82 | CES2 (0.62) | CES2MEN1KMT2ANPSR1SRD5A2 | |
| SCHEMBL18371866 | 0.82 | CES2 (0.79) | CES2MEN1KMT2ANPSR1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912606-A | Catalyst suitable for ethylene polymerization reaction and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-119912606-A | Catalyst suitable for ethylene polymerization reaction and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-2560963-B1 | PYRAZINE DERIVATIVES AS INHIBITORS OF THE ENZYME SCD-1 FOR THE TREATMENT OF CANCER DISEASES AND DIABETES | PF MEDICAMENT (FR) | 2016-10-05 | — | — | EP | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2454239-B1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8592459-B2 | Substituted benzimidazoles and methods of their use | NOVARTIS AG (CH) | 2013-11-26 | — | — | US | disclosed |
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| US-7732465-B2 | Substituted benzimidazoles and methods of their use | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20090170904-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009079001-A1 | BICYCLIC HETEROARYL-SUBSTITUTED IMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | KINDRACHUK DAVID E | 2009-06-18 | — | — | US | disclosed |
| US-7482367-B2 | Substituted benzimidazoles and methods of their use | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080287682-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2008-11-20 | — | — | US | disclosed |
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2007-07-12 | — | — | US | disclosed |
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2007-03-01 | — | — | US | disclosed |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | ABL1, CDK2, KIT | CES2 1452/4885MEN1 1855/4885KMT2A 1063/4885 |
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | BRAF, DSTYK, CHEK2 | CES2 2911/4885MEN1 2903/4885KMT2A 860/4885 |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PRMT1, NNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CES2 1829/4885MEN1 321/4885KMT2A 1650/4885 |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | CES2 4836/4885MEN1 3564/4885KMT2A 3156/4885 |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | HRH4, HRH3, HRH1 | CES2 3530/4885MEN1 2415/4885KMT2A 580/4885 |
| US-20090170904-A1 | Substituted benzimidazoles and methods of their use | BRAF, DSTYK, CHEK2 | CES2 2911/4885MEN1 2903/4885KMT2A 860/4885 |
| US-20080287682-A1 | Substituted benzimidazoles and methods of preparation | ABL1, CDK2, KIT | CES2 1452/4885MEN1 1855/4885KMT2A 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.